This new class of therapeutics is based on the combination of metal ions of known therapeutic potential with a novel proprietary pharmaceutical ingredient, BP.  BP-C1 consists of the BP ligand combined with platinum, and BP-C2 consists of the BP molecule combined with molybdenum.

Therapeutic Pipeline

  About us R&D News Investor Contact
   
   
BP-C110S
BP-C100
BP-C2
BP-C109
BP-Cx1
BP-C4
 
 

Meabco’s products consist of a novel class of therapeutics offering significant competitive advantages over existing drugs, by having good clinical efficacy, low production costs and very few adverse side effects.

 

 

 

 

 

 

BP-C127
BP-C3
BP-C132

 

 

 

 

 

 

 

 

 

 
Copyright © 2004 Meabco  All rights reserved